Clinical Trials Logo

Stage IV Non-small Cell Lung Cancer clinical trials

View clinical trials related to Stage IV Non-small Cell Lung Cancer.

Filter by:
  • Withdrawn  
  • Page 1 ·  Next »

NCT ID: NCT03023904 Withdrawn - Clinical trials for Stage IV Non-Small Cell Lung Cancer

Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads

Start date: December 29, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well nivolumab works in treating patients with stage IV lung cancer or that has come back after initial treatment who has high mutation loads. Monoclonal antibodies, such as nivolumab, may block tumor growth in different ways by targeting certain cells.

NCT ID: NCT02831491 Withdrawn - Clinical trials for Stage IV Non-small Cell Lung Cancer

A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer

Start date: November 2016
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to evaluate the safety of the study drug ramucirumab in combination with weekly docetaxel in participants with stage IV non-small cell lung cancer (NSCLC) following disease progression after prior platinum-based chemotherapy.

NCT ID: NCT02567396 Withdrawn - Clinical trials for Stage IV Non-Small Cell Lung Cancer

Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

Start date: June 2016
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of talazoparib in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or have spread to other places in the body (metastatic) and cannot be removed by surgery and liver or kidney dysfunction. Talazoparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT02451865 Withdrawn - Clinical trials for Stage IV Non-Small Cell Lung Cancer

Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung Cancer

Start date: June 2016
Phase: Phase 1
Study type: Interventional

This phase Ib trial studies the safety and best dose of binimetinib when given in combination with docetaxel in treating patients with previously treated, stage IV non-small cell lung cancer. Binimetinib and docetaxel may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT02106559 Withdrawn - Clinical trials for Stage IV Non-small Cell Lung Cancer

Photodynamic Therapy During Surgery in Treating Patients With Pleural Malignancy

Start date: September 2014
Phase: N/A
Study type: Interventional

This pilot clinical trial studies photodynamic therapy during surgery in treating patients with pleural (the protective lining or membrane that covers the lungs and chest cavity) malignancy. Photodynamic therapy is an anti-cancer treatment that combines a photosensitizer (a substance that makes cells more sensitive to light), such as porfimer sodium, together with oxygen and visible light to kill tumor cells and/or damage the tumor's blood supply. Intraoperative (during surgery) photodynamic therapy may kill any tumor cells that remain after surgery.

NCT ID: NCT02017925 Withdrawn - Fatigue Clinical Trials

Pulmonary Rehabilitation in Improving Lung Function in Patients With Locally Advanced Non-Small Cell Lung Cancer Undergoing Chemoradiation

Start date: October 2013
Phase: N/A
Study type: Interventional

This randomized clinical trial studies pulmonary rehabilitation in improving lung function in patients with locally advanced non-small cell lung cancer undergoing chemoradiation. Individualized exercise rehabilitation programs may reduce breathing problems and improve quality of life in patients with non-small cell lung cancer. It is not yet known whether pulmonary rehabilitation is more effective when started during or after cancer treatment.

NCT ID: NCT01971489 Withdrawn - Clinical trials for Stage IV Non-Small Cell Lung Cancer

Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors

Start date: September 2015
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and the best doses of buparlisib, gemcitabine hydrochloride, and cisplatin in treating patients with solid tumors that have spread to other places in the body. Buparlisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving buparlisib, gemcitabine hydrochloride, and cisplatin may be a better treatment for solid tumors.

NCT ID: NCT01928160 Withdrawn - Clinical trials for Stage IV Non-small Cell Lung Cancer

Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib

Start date: June 2014
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well pemetrexed disodium and carboplatin or cisplatin with or without erlotinib hydrochloride work in treating patients with epidermal growth factor receptor (EGFR) mutant positive stage IV non-small cell lung cancer and acquired resistance to first-line therapy with erlotinib hydrochloride or gefitinib. In patients that develop resistance to first-line therapy with EGFR tyrosine kinase inhibitors (TKIs) the drug is usually stopped and the patient is switched to chemotherapy. Drugs used in chemotherapy, such as pemetrexed disodium, carboplatin, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether pemetrexed disodium and carboplatin or cisplatin is more effective with or without erlotinib hydrochloride in treating patients with EGFR mutant non-small cell lung cancer and acquired resistance to EGFR TKIs.

NCT ID: NCT01383668 Withdrawn - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer

Start date: June 2011
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of sirolimus and gold sodium thiomalate when given together in treating patients with advanced squamous non-small cell lung cancer (NSCLC). Sirolimus and gold sodium thiomalate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth

NCT ID: NCT01325753 Withdrawn - Clinical trials for Stage IV Non-small Cell Lung Cancer

Cryotherapy in Treating Patients With Lung Cancer That Has Spread to the Other Lung or Parts of the Body

Start date: March 2011
Phase: N/A
Study type: Interventional

This pilot clinical trial studies the side effects of cryotherapy (cryoablation [CA]) in treating patients with lung cancer. Cryotherapy kills cancer cells by freezing them.